Hetero (India) receives approval from the Drug Controller General of India to market 'COVIFOR'; a generic of the investigational antiviral drug 'Remdesivir'.
The drug, developled by Gilead Lifesciences Inc. was granted Emergency Use Authorisation by the USFDA last month, for the treatment of suspected or laboratory confirmed COVID-19 in adults and children hospitalised with severe disease.
Hetero launched its product under a licensing agreement with Gilead Lifesciences Inc.
George Steuart Health has partnered with Hetero to make the product available in Sri Lanka.